7 patents currently held
6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Dec 2036. from the record
Of the 6 now held by other companies, 6 name Ucb Biosciences Inc. as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Dec 2036
Next term end
3
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Aug 2037 · Medium confidence
Also notable
Ends Dec 2036 · High confidence
Also notable
Ends Aug 2037 · Medium confidence
Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same
US 11,786,487
Cited by 10 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2037. A terminal disclaimer caps this term to an earlier patent's.
Fenfluramine Compositions and Methods of Preparing the Same
US 11,634,377
Cited by 12 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2036.
Methods of Treating Lennox-Gastaut Syndrome Using Fenfluramine
US 12,734,137
Granted 2026. Too new for citation comparison; protection runs to 2037. A terminal disclaimer caps this term to an earlier patent's.
Formerly held, still cited
Notable
Ends Apr 2039 · High confidence
Cited by 4 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2039.
now held by Ucb Biosciences, Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 19, 2027The maintenance fee for Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same (US 11,759,440) comes due Mar 19, 2027. Unpaid by Sep 20, 2027, it lapses early.
- 1 fee due Apr 17, 2027The maintenance fee for Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same (US 11,786,487) comes due Apr 17, 2027. Unpaid by Oct 18, 2027, it lapses early.
- 1 fee due Sep 30, 2027The maintenance fee for Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same (US 10,603,290) comes due Sep 30, 2027. Unpaid by Mar 31, 2028, it lapses early.
Recent changes
- 3 of the patents on this record were granted since Aug 16, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same | 5 in force | to Aug 2037 |
| Methods of Treating Lennox-Gastaut Syndrome Using Fenfluramine | 1 in force | to Aug 2037 |
| Fenfluramine Compositions and Methods of Preparing the Same | 1 in force | to Dec 2036 |
Patents held now
Soonest term end first.
Showing 1 to 7 of 7
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,634,377 | Fenfluramine Compositions and Methods of Preparing the Same held by Zogenix International Limited In force · High confidence | In force | High confidence | |
| US 10,603,290 | Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same held by Zogenix International Limited In force · Medium confidence | In force | Medium confidence | |
| US 11,040,018 | Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same held by Zogenix International Limited In force · Medium confidence | In force | Medium confidence | |
| US 11,406,606 | Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same held by Zogenix International Limited In force · Medium confidence | In force | Medium confidence | |
| US 11,759,440 | Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same held by Zogenix International Limited In force · Medium confidence | In force | Medium confidence | |
| US 11,786,487 | Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same held by Zogenix International Limited In force · Medium confidence | In force | Medium confidence | |
| US 12,734,137 | Methods of Treating Lennox-Gastaut Syndrome Using Fenfluramine held by Zogenix International Limited In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 7: 6 patents in force now held by others · 30 patents ended · 6 applications pending · 23 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.